Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
DBV Technologies is a clinical-stage biopharmaceutical company developing innovative immunotherapies for food allergies and immune-related conditions. Its proprietary Viaskin platform delivers allergens via skin patches to induce desensitization safely and non-invasively. Focused on peanut allergy, the company advances its products through clinical trials targeting children, aiming to provide effective, convenient treatments that address unmet medical needs in allergy management.
This description was generated via AI from an annual report. Updated about 1 year ago.